about
Glypican-3 Targeting Immunotoxins for the Treatment of Liver CancerAntibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dinutuximab: A Review in High-Risk Neuroblastoma.
@en
type
label
Dinutuximab: A Review in High-Risk Neuroblastoma.
@en
prefLabel
Dinutuximab: A Review in High-Risk Neuroblastoma.
@en
P2860
P1433
P1476
Dinutuximab: A Review in High-Risk Neuroblastoma.
@en
P2093
Sheridan M Hoy
P2860
P2888
P304
P356
10.1007/S11523-016-0420-2
P577
2016-02-19T00:00:00Z
P6179
1012948001